Catalogs from Absea
Spatial Pathology – IHC-Validated Antibody Series
Immunohistochemistry enables the precise detection of proteins in cells and tissues through specific antigen–antibody interactions. It is essential for accurate disease diagnosis, guiding targeted therapies, and advancing spatial proteomics by mapping protein distribution within tissue context. Biomarkers such as Ki67, p53, CK20, CK7, and PD-L1 are key to early cancer detection, making reliable antibody tools indispensable. The IHC-Validated Antibody Series by Absea® Biotechnology offers high specificity, a portfolio of over 2,400 validated targets, and trusted performance—empowering research and diagnostics with confidence. Released September 2025.
Immunoglobulins – Recombinant Human Immunoglobulins and Ig-Targeting mAbs
Accurate antibody typing is essential for identifying immunoglobulin isotypes, subtypes, and light chains. This is critical for research into IgG4-related diseases, autoimmune disorders, IgG subclass deficiencies, hypersensitivity reactions, and infectious diseases. Absea® Biotechnology provides a comprehensive portfolio of high-quality mAbs—including IgG1–4, IgA, IgE, IgM, and Kappa and Lambda light chains—available with magnetic beads for isotyping and subtyping. These antibodies offer high specificity, no cross-reactivity, and isotype-specific IP beads, supporting reliable research and diagnostic applications. Released September 2025.
Targeting the E3ome – Ubiquitination-Modulating Proteins and Validated Antibodies
Targeted Protein Degradation opens new possibilities for tackling “undruggable” targets, improving drug selectivity, and overcoming resistance from protein mutations. Its advancement relies on effective target detection, discovery of versatile E3 ligases, and reduction of off-target effects. Leveraging a leading human protein library and advanced antibody platform, Absea® has developed over 400 ubiquitination-modulating protein constructs and validated antibodies for more than 140 targets. Through the E3ome program, Absea® delivers essential tools to identify E3 ligases, map their substrates, and drive TPD innovation. Released September 2025.
MHC – mAbs for Immunopeptidomics
The Absea® MHC Antibody Project develops highly specific antibodies to detect and study MHC molecules and the peptides they present. Immunopeptidomics provides crucial data on these peptides, helping identify which are most relevant for further investigation. In vaccine development and immunotherapy, this approach reveals key antigenic peptides that serve as therapeutic targets. MHC antibodies developed against these targets support disease diagnostics, biomarker discovery, and research into antigen presentation, cancer, and infectious diseases. Released September 2025.